Cytostatic Effect of Repeated Exposure to Simvastatin: A Mechanism for Chronic Myotoxicity Revealed by the Use of Mesodermal Progenitors Derived from Human Pluripotent Stem Cells
August 6, 2015
July 1, 2015.
[EVENTS] Company
Vincent Petit, CEO of METAFORA Biosystems, took the stage at the First International Meeting of Biotechnology in Paris, on July 1st, 2015.
Organized by BPI France and the French Pharmaceutical Association (LEEM), this prestigious event aimed to bridge the gap between innovative biotech companies and major pharmaceutical players.
During his presentation, Vincent outlined the strategic plans of METAFORA Biosystems, emphasizing the company’s commitment to advancing diagnostic solutions for rare diseases. He highlighted the innovative approaches the company is taking to develop cutting-edge technologies that can significantly improve patient outcomes.
The event featured 17 selected French biotech companies, each showcasing their unique projects and potential for collaboration. METAFORA was chosen for its ambitious goals and groundbreaking work in the field of diagnostics, particularly in the context of rare metabolic disorders.
Vincent underscored the importance of forming partnerships with international pharmaceutical companies to accelerate research and development. By fostering collaborative efforts, METAFORA aims to leverage the expertise and resources of larger organizations, ultimately driving innovation and bringing new diagnostic tools to market more efficiently.
About the event organizer
The first International Biotechnology Meeting focused on rare diseases is especially designed to bring together selected French biotechnology companies and major worldwide pharmaceutical companies.
This meeting served as a vital platform for networking and establishing connections with key players in the pharmaceutical industry. The potential partnerships that emerged from this event could pave the way for significant advancements in biotechnology and healthcare.
As METAFORA Biosystems continues its journey in the biotech landscape, the insights shared by Vincent at this meeting reflect the company’s dedication to innovation and its vision for a healthier future. The collaboration with international big pharma could be a game-changer in the quest to address unmet medical needs and improve the lives of patients worldwide.
